Increase in transglutaminase 2 in idiopathic inflammatory myopathies

被引:25
作者
Choi, YC
Kim, TS
Kim, SY
机构
[1] Yonsei Univ, Coll Med, Brain Korea Project Med 21, Dept Neurol, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Brain Korea Project Med 21, Dept Pathol, Seoul, South Korea
[3] Cornell Univ, Weill Med Coll, Dept Neurosci, New York, NY USA
[4] Burke Med Res Inst, New York, NY USA
关键词
transglutaminase; inflammatory myopathies; dermatomyositis; polymyositis; Duchenne muscular dystrophy;
D O I
10.1159/000074911
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Idiopathic inflammatory myopathies (IMs), including dermatomyositis (DM), polymyositis ( PM), and sporadic inclusion body myositis (s-IBM), are characterized by inflammatory cell infiltration in muscle tissue and muscle fiber destruction, which leads to muscle weakness. Although the cause of IMs is unclear, an autoimmune pathogenesis may be involved in initiating the muscle inflammation. Recently, we have found an aberrant expression of transglutaminase 2 ( TGase 2) in s-IBM, which is closely associated with insoluble inclusion body formation. TGase 2 is a cross-linking enzyme that generates a conformational change of molecules via a covalent isopeptide bond. The increase in the level of TGase 2 expression and the inappropriate presentation of substrates/ cross-linked aggregates to the immune system may contribute to the autoimmune aspects of IMs. We investigated whether or not an increase in TGase 2 expression is a common factor in muscle inflammation. Duchenne muscular dystrophy (DMD) and normal tissues were employed as controls. Using immunocytochemistry and quantitative RT-PCR, the level of TGase 2 expression was found to be specifically increased in PM and DM, but not in DMD and normal controls. Therefore, the targeting of TGase inhibition in IMs will be a challenging therapeutic approach that should be investigated in the near future. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:10 / 14
页数:5
相关论文
共 33 条
[1]  
AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308
[2]  
Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437
[3]   Sporadic inclusion-body myositis and hereditary inclusion-body myopathies - Diseases of oxidative stress and aging? [J].
Askanas, V ;
Engel, WK .
ARCHIVES OF NEUROLOGY, 1998, 55 (07) :915-920
[4]   INHIBITION OF THE FORMATION OF MYOTUBES INVITRO BY INHIBITORS OF TRANSGLUTAMINASE [J].
BERSTEN, AM ;
AHKONG, QF ;
HALLINAN, T ;
NELSON, SJ ;
LUCY, JA .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 762 (03) :429-436
[5]  
BOUABOULA M, 1992, J BIOL CHEM, V267, P21830
[6]   TRANSGLUTAMINASE-CATALYZED CROSS-LINKING - A POTENTIAL MECHANISM FOR THE INTERACTION OF FIBRINOGEN, LOW-DENSITY LIPOPROTEIN AND ARTERIAL TYPE-III PROCOLLAGEN [J].
BOWNESS, JM ;
TARR, AH ;
WIEBE, RI .
THROMBOSIS RESEARCH, 1989, 54 (04) :357-367
[7]   Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2 [J].
Choi, YC ;
Park, GT ;
Kim, TS ;
Sunwoo, IN ;
Steinert, PM ;
Kim, SY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8703-8710
[8]   Treatment of dermatomyositis and polymyositis [J].
Choy, EHS ;
Isenberg, DA .
RHEUMATOLOGY, 2002, 41 (01) :7-13
[9]   Regulation of the dual function tissue transglutaminase/Gαh during murine neuromuscular development:: gene and enzyme isoform expression [J].
Citron, BA ;
Gregory, EJ ;
Steigerwalt, DS ;
Qin, F ;
Festoff, BW .
NEUROCHEMISTRY INTERNATIONAL, 2000, 37 (04) :337-349
[10]   Molecular immunology and genetics of inflammatory muscle diseases [J].
Dalakas, MC .
ARCHIVES OF NEUROLOGY, 1998, 55 (12) :1509-1512